Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.

The modular sterile filling system reportedly can deliver 500 to 50,000 units per batch specifically tailored for process development.

Uniphar is expanding its footprint with new facilities in the United States and elsewhere to better support pharma and medtech manufacturers.